To evaluate whether adding humanized monoclonal insulin growth factor-1 receptor (IGF-1R) antibody (dalotuzumab) to mammalian target of rapamycin (mTOR) inhibitor (ridaforolimus) plus aromatase inhibitor (exemestane) improves outcomes in patients with estrogen receptor (ER)-positive advanced/metastatic breast cancer.
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer / Rugo, H.S., Trédan, O., Ro, J., Morales, S.M., Campone, M., Musolino, A., Afonso, N., Ferreira, M., Park, K.H., Cortes, J., Tan, A.R., Blum, J.L., Eaton, L., Gause, C.K., Wang, Z., Im, E., Mauro, D.J., Jones, M.B., Denker, A., Baselga, J.. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 165:3(2017), p. 601-609. [10.1007/s10549-017-4375-5]
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
Musolino, AntoninoInvestigation
;
2017-01-01
Abstract
To evaluate whether adding humanized monoclonal insulin growth factor-1 receptor (IGF-1R) antibody (dalotuzumab) to mammalian target of rapamycin (mTOR) inhibitor (ridaforolimus) plus aromatase inhibitor (exemestane) improves outcomes in patients with estrogen receptor (ER)-positive advanced/metastatic breast cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
